(Q39202496)

English

Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts

scientific article published on 30 January 2013

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Perifosine and sorafenib combination induces mitochondrial cell death and antitumor effects in NOD/SCID mice with Hodgkin lymphoma cell line xenografts (English)

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

1 reference

based on heuristic

inferred from title

Hodgkin lymphoma

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Arianna Giacomini

2

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Andrea Anichini

6

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

author name string

S L Locatelli

1

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

A Guidetti

3

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

L Cleris

4

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

R Mortarini

5

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

A M Gianni

7

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

C Carlo-Stella

8

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

publication date

30 January 2013

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

27

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

8

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

1677-1687

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Cancer treatment and survivorship statistics, 2012

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Management of Hodgkin lymphoma in relapse after autologous stem cell transplant.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Beyond chemotherapy: new agents for targeted treatment of lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

From Hodgkin disease to Hodgkin lymphoma: biologic insights and therapeutic potential

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Emerging drugs for Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Novel treatment strategies for patients with relapsed classical Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Perifosine as a potential novel anti-cancer agent inhibits EGFR/MET-AKT axis in malignant pleural mesothelioma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Coadministration of histone deacetylase inhibitors and perifosine synergistically induces apoptosis in human leukemia cells through Akt and ERK1/2 inactivation and the generation of ceramide and reactive oxygen species

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Phase II study of sorafenib in patients with relapsed or refractory lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Hodgkin's disease: establishment and characterization of four in vitro cell lies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Hodgkin's disease derived cell lines HDLM-2 and L-428: comparison of morphology, immunological and isoenzyme profiles

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Characterization of a novel Hodgkin cell line, HD-MyZ, with myelomonocytic features mimicking Hodgkin's disease in severe combined immunodeficient mice.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

IFN-gamma enhances the antimyeloma activity of the fully human anti-human leukocyte antigen-DR monoclonal antibody 1D09C3.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

The anti-human leukocyte antigen-DR monoclonal antibody 1D09C3 activates the mitochondrial cell death pathway and exerts a potent antitumor activity in lymphoma-bearing nonobese diabetic/severe combined immunodeficient mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Human CD34+ cells engineered to express membrane-bound tumor necrosis factor-related apoptosis-inducing ligand target both tumor cells and tumor vasculature

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Targeting cancer with small molecule kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

TRB3: a tribbles homolog that inhibits Akt/PKB activation by insulin in liver

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Human tribbles, a protein family controlling mitogen-activated protein kinase cascades

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Identification of RIP1 kinase as a specific cellular target of necrostatins

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Mammalian target of rapamycin inhibitors and their potential role in therapy in leukaemia and other haematological malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

TRB3, a novel ER stress-inducible gene, is induced via ATF4-CHOP pathway and is involved in cell death

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

The kinase inhibitor sorafenib induces cell death through a process involving induction of endoplasmic reticulum stress

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Anti-tumoral action of cannabinoids on hepatocellular carcinoma: role of AMPK-dependent activation of autophagy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Perifosine: update on a novel Akt inhibitor.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Sorafenib and vorinostat kill colon cancer cells by CD95-dependent and -independent mechanisms

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Sorafenib enhances pemetrexed cytotoxicity through an autophagy-dependent mechanism in cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Perifosine induces differentiation and cell death in prostate cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Oncogenic stress induced by acute hyper-activation of Bcr-Abl leads to cell death upon induction of excessive aerobic glycolysis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Necroptosis as an alternative form of programmed cell death

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

AIF-mediated caspase-independent necroptosis requires ATM and DNA-PK-induced histone H2AX Ser139 phosphorylation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Inhibition of MEK/ERK1/2 sensitizes lymphoma cells to sorafenib-induced apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Pharmacodynamic markers of perifosine efficacy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Analyzing primary Hodgkin and Reed-Sternberg cells to capture the molecular and cellular pathogenesis of classical Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Hematological cancer in 2011: New therapeutic targets and treatment strategies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

21 January 2018

Developments in the management of Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.28

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2013.28

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Dimensions Publication ID

0 references

release_vdlh5oajmbe2houd7m4hpeu6ja

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

9 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39202496&oldid=2202676282"